<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35344122</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-4994</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of fluorescence</Title>
          <ISOAbbreviation>J Fluoresc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Synchronous Fluorescence as a Green and Selective Method for the Simultaneous Determination of Cetirizine and Azelastine in Aqueous Humor.</ArticleTitle>
        <Pagination>
          <StartPage>1199</StartPage>
          <EndPage>1210</EndPage>
          <MedlinePgn>1199-1210</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10895-022-02913-6</ELocationID>
        <Abstract>
          <AbstractText>A green, simple, quick and economical method is implemented for the first time for the simultaneous estimation of cetirizine (CTZ) and azelastine (AZE) as co-administered eye drops. The method relies on synchronous spectrofluorimetry with ∆λ = 60 nm. Cetirizine can be estimated at 231 nm and AZE can be measured at 294 nm, each at the other's zero crossing point. All factors affecting the method were studied and properly optimized. Good correlation was obtained in the range of 0.1-2 µg mL<sup>-1</sup> for both drugs. The limits of detection were 0.014 and 0.010 µg mL<sup>-1</sup> and limits of quantitation were 0.043 and 0.029 µg mL<sup>-1</sup> for CTZ and AZE, respectively. Moreover, ICH guidelines were carried out to validate the adopted method. The method was suitable for the analysis of CTZ and AZE in synthetic mixtures, eye drops and aqueous humor. The mean percentage of recoveries of CTZ and AZE in spiked aqueous humor were 99.83 and 99.37, respectively. Furthermore, Green Analytical Procedure Index (GAPI) and analytical Eco-scale approaches were used to evaluate the greenness of the suggested method.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Abd-AlGhafar</LastName>
            <ForeName>Walaa Nabil</ForeName>
            <Initials>WN</Initials>
            <Identifier Source="ORCID">0000-0003-1489-4239</Identifier>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Mansoura University, Mansoura, 35516, Egypt. walaanabil246@mans.edu.eg.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Aly</LastName>
            <ForeName>F A</ForeName>
            <Initials>FA</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Mansoura University, Mansoura, 35516, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sheribah</LastName>
            <ForeName>Zeinab A</ForeName>
            <Initials>ZA</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Mansoura University, Mansoura, 35516, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Saad</LastName>
            <ForeName>Samar</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Mansoura University, Mansoura, 35516, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Fluoresc</MedlineTA>
        <NlmUniqueID>9201341</NlmUniqueID>
        <ISSNLinking>1053-0509</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D009883">Ophthalmic Solutions</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010793">Phthalazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YO7261ME24</RegistryNumber>
          <NameOfSubstance UI="D017332">Cetirizine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>ZQI909440X</RegistryNumber>
          <NameOfSubstance UI="C020976">azelastine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001082" MajorTopicYN="Y">Aqueous Humor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017332" MajorTopicYN="Y">Cetirizine</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009883" MajorTopicYN="N">Ophthalmic Solutions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010793" MajorTopicYN="N">Phthalazines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013050" MajorTopicYN="N">Spectrometry, Fluorescence</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Aqueous humor</Keyword>
        <Keyword MajorTopicYN="N">Azelastine</Keyword>
        <Keyword MajorTopicYN="N">Cetirizine</Keyword>
        <Keyword MajorTopicYN="N">Eye Drops</Keyword>
        <Keyword MajorTopicYN="N">Synchronous Fluorimetry</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>12</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35344122</ArticleId>
        <ArticleId IdType="pmc">PMC9095524</ArticleId>
        <ArticleId IdType="doi">10.1007/s10895-022-02913-6</ArticleId>
        <ArticleId IdType="pii">10.1007/s10895-022-02913-6</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2020;124:118–134. doi: 10.1016/j.anai.2019.11.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anai.2019.11.014</ArticleId>
            <ArticleId IdType="pubmed">31759180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyazaki D, Fukagawa K, Okamoto S, Fukushima A, Uchio E, Ebihara N, Shoji J, Namba K, Shimizu Y. Eidemiological aspects of allergic conjunctivitis. Allergol Int. 2020;69:487–495. doi: 10.1016/j.alit.2020.06.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.alit.2020.06.004</ArticleId>
            <ArticleId IdType="pubmed">32654975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeremy Ono S, Abelson MB. Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118–122. doi: 10.1016/j.jaci.2004.10.042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2004.10.042</ArticleId>
            <ArticleId IdType="pubmed">15637556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bielory L, Friedlaender MH. Allergic Conjunctivitis. Immunol Allergy Clin North Am. 2008;28:43–58. doi: 10.1016/j.iac.2007.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.iac.2007.12.005</ArticleId>
            <ArticleId IdType="pubmed">18282545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>British Pharmacopoeia (2017) The Stationary Office: electronic version Volume I &amp; II, London.</Citation>
        </Reference>
        <Reference>
          <Citation>Malhotra RP, Meier E, Torkildsen G, Gomes PJ, Jasek MC. Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects. Clin Ophthalmol. 2019;13:403–413. doi: 10.2147/OPTH.S186092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OPTH.S186092</ArticleId>
            <ArticleId IdType="pmc">PMC6387590</ArticleId>
            <ArticleId IdType="pubmed">30858690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The United States Pharmacopoeia (2017) 40th edn. and National Formulary 35th edn. U.S. Pharmacopoeial Convention, Rockville.</Citation>
        </Reference>
        <Reference>
          <Citation>Ma M, Feng F, Sheng Y, Cui S, Liu H. Development and evaluation of an efficient HPLC/MS/MS method for the simultaneous determination of pseudoephedrine and cetirizine in human plasma: Application to Phase-I pharmacokinetic stud. J Chromatogr B. 2007;846:105–111. doi: 10.1016/j.jchromb.2006.08.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jchromb.2006.08.026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souri E, Hatami A, Ravari NS, Alvandifar F, Tehrani MB. Validating a stability indicating HPLC method for kinetic study of cetirizine degradation in acidic and oxidative conditions. Iran J Pharm Res. 2013;12:287–294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3813251</ArticleId>
            <ArticleId IdType="pubmed">24250602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aly FA, EL-Enany N, Elmansi H, Nabil AA (2017) Validated reversed phase hplc method for simultaneous determination of the antihistaminic cetirizine and beta2-adrenergic agonist salbutamol in their co-formulated tablets. SM anal bioanal technique 2</Citation>
        </Reference>
        <Reference>
          <Citation>Shamshad H, Mirza AZ. Application of RP-HPLC method for the simultaneous determination of cetirizine in the presence of quinolones. Future J Pharm Sci. 2021;7:1–6. doi: 10.1186/s43094-020-00150-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s43094-020-00150-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shamshad H, Sayqal A, Zeb J, Mirza AZ (2021) Simultaneous determination of chloroquine and pyrimethamine with cetirizine in an active form and human serum by RP-HPLC. J Chromatogr Sci bmab018</Citation>
        </Reference>
        <Reference>
          <Citation>Uysal UD, Tunçel M. Validated capillary electrophoresis study for the determination of cetirizine in pharmaceutical forms. J Liq Chromatogr Relat Technol. 2006;29:1781–1792. doi: 10.1080/10826070600716983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10826070600716983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Javid FS, Shafaat A, Zarghi A. Determination of cetirizine and its impurities in bulk and tablet formulation using a validated capillary zone electrophoretic method. J Anal Chem. 2014;69:442–447. doi: 10.1134/S1061934814050037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1134/S1061934814050037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibrahim F, El-Din MS, Eid M, Wahba MEK. Spectrofluorimetric determination of some H1 receptor antagonist drugs in pharmaceutical formulations and biological fluids. Int J Pharm Sci and Res. 2011;2:2056–2072.</Citation>
        </Reference>
        <Reference>
          <Citation>Wei XL, Lei XR, Gong Q, Wang LS, Liao Y. Determination of cetirizine dihydrochloride by anti-fluorescence quenching on rhodamine B-Sodium tetraphenylborate system. Guang Pu Xue Yu Guang Pu Fen Xi. 2011;31:1596–1600.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21847941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Din MKS, Ibrahim F, Eid MI, Wahba MEK. Validated spectroflurimetric determination of some H1 receptor antagonist drugs in pharmaceutical preparations through charge transfer complexation. J Fluoresc. 2012;22:175–191. doi: 10.1007/s10895-011-0944-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10895-011-0944-x</ArticleId>
            <ArticleId IdType="pubmed">21830038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Kommos ME, El-Gizawy SM, Atia NN, Hosny NM. Determination of some non-sedating antihistamines via their native fluorescence and derivation of some quantitative fluorescence intensity - structure relationships. J Fluoresc. 2015;25:1695–1709. doi: 10.1007/s10895-015-1656-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10895-015-1656-4</ArticleId>
            <ArticleId IdType="pubmed">26439930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pourghazi K, Khoshhesab ZM, Golpayeganizadeh A, Shapouri MR, Afrouzi H. Spectrophotometric determination of cetirizine and montelukast in prepared formulations. Int J Pharm Pharm Sci. 2011;3:128–130.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Didamony AM, Ramadan GM. Charge-transfer interaction between antihistamine antiallergic drugs, diphenhydramine, fexofenadine, cetirizine and two π-acceptors in pharmaceutical forms. SN Appl Sci. 2020;2:1–14. doi: 10.1007/s42452-020-2402-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s42452-020-2402-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambiase A, Micera A, Bonini S. Multiple action agents and the eye: do they really stabilize mast cells? Curr Opin Allergy Clin Immunol. 2009;9:454–465. doi: 10.1097/ACI.0b013e3283303ebb.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/ACI.0b013e3283303ebb</ArticleId>
            <ArticleId IdType="pubmed">19652595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Shaheny RN, Yamada K. Stability study of the antihistamine drug azelastine HCl along with a kinetic investigation and the identification of new degradation products. Anal Sci. 2014;30:691–697. doi: 10.2116/analsci.30.691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2116/analsci.30.691</ArticleId>
            <ArticleId IdType="pubmed">24919676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassouna M, Abdelrahman M, Abdelfatah M. Simultaneous determination of azelastine hydrochloride and benzalkonium chloride by RP-HPLC method in their ophthalmic solution. J Forensic Sci Crim Investig. 2017;1:555–565.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel S, Pasha TY. Stability-indicating high-performance liquid chromatography method for determination of antihistamine drug azelastine. Asian J Pharm Clin Res. 2018;11:248–251. doi: 10.22159/ajpcr.2018.v11i8.25506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.22159/ajpcr.2018.v11i8.25506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Masry AA, Hammouda MEA, El-Wasseef DR, El-Ashry SM. Eco-friendly green liquid chromatographic determination of azelastine in the presence of its degradation products: Applications to degradation kinetics. J AOAC Int. 2019;102:81–90. doi: 10.5740/jaoacint.17-0472.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5740/jaoacint.17-0472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Masry AA, Hammouda ME, El-Wasseef DR, El-Ashry SM. Eco-friendly green liquid chromatographic separations of a novel combination of azelastine and fluticasone in the presence of their pharmaceutical dosage form additives. Curr Anal Chem. 2020;16:277–286. doi: 10.2174/1573411014666180727130722.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1573411014666180727130722</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salama NN, Abdel-Razeq SA, Abdel-Atty S, El-Kosy N. Development and validation of densitometry TLC stability indicating method for quantitative determination of azelastine hydrochloride and emedastine difumarate in their drug products. J Pharm Res Int. 2014;4:79–92.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel KG, Patel SKG, Shah PA, Tandel DB, Gandhi TR. Development and validation of HPTLC method along with forced degradation study for the simultaneous estimation of azelastine hydrochloride and fluticasone propionate in nasal spray formulation using design of experiment approach. Indian J Pharm Educ Res. 2020;54:155–165. doi: 10.5530/ijper.54.1.19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5530/ijper.54.1.19</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adelwahab NS, Farid NF, Elagawany M, Abdelmomen EH (2018) Efficient UPLC and CE methods for the simultaneous determination of azelastine hydrochloride and its genotoxic impurity. Biomed Chromatogr 32:e4346</Citation>
        </Reference>
        <Reference>
          <Citation>Abdel-Razeq SA, Foaud MM, Salama NN, Abdel-Atty S, El- Kosy N. Voltammetric determination of azelastine-HCl and emedastine difumarate in micellar solution at glassy carbon and carbon paste electrodes. Sensing in Electroanalysis. 2011;6:289–305.</Citation>
        </Reference>
        <Reference>
          <Citation>Elghobashy MR, Badran OM, Salem MY, Kelani KM. Application of membrane selective electrodes for the determination of azelastine hydrochloride in the presence of its alkaline degradant in eye drops and plasma. J Anal Bioanal Electrochem. 2013;5:325–340.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Masry AA, El-Wasseef DR, Eid M, Shehata IA, Zeid AM (2021) Quantitative proton nuclear magnetic resonance method for simultaneous analysis of fluticasone propionate and azelastine hydrochloride in nasal spray formulation. R Soc Open Sci 8:210483</Citation>
        </Reference>
        <Reference>
          <Citation>El-Masry AA, Hammouda MEA, El-Wasseef DR, El-Ashry SM. Validated sensitive spectrofluorimetric method for determination of antihistaminic drug azelastine HCl in pure form and in pharmaceutical dosage forms: application to stability study. Luminescence. 2017;32:177–181. doi: 10.1002/bio.3164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/bio.3164</ArticleId>
            <ArticleId IdType="pubmed">27279096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ragab MAA, El-Kimary EI. Investigation of the spectrofluorimetric behavior of azelastine and nepafenac: Determination in ophthalmic dosage forms. Spectrochim Acta A. 2018;204:260–266. doi: 10.1016/j.saa.2018.06.057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.saa.2018.06.057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shekhar S, Bali A. Spectrofluorimetric method for the determination of azelastine hydrochloride in bulk and nasal formulations. J Appl Spectrosc. 2021;88:674–680. doi: 10.1007/s10812-021-01224-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10812-021-01224-1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gouda AA, El Sheikh R, El Saied H. Extractive spectrophotometric determination of azelastine hydrochloride in pure form and pharmaceutical formulations. Can Chem Trans. 2015;3:29–41.</Citation>
        </Reference>
        <Reference>
          <Citation>Hassouna MEM, Abdelrahman MM, Mohamed MA. Determination of azelastine hydrochloride and benzalkonium chloride in their ophthalmic solution by different spectrophotometric methods. World J Appl Chem. 2017;2:48–56.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Masry AA, Hammouda MEA, El-Wasseef DR, El-Ashry SM. Validated spectroscopic methods for determination of anti-histaminic drug azelastine in pure form: Analytical application for quality control of its pharmaceutical reparations. Spectrochim Acta A. 2018;191:413–420. doi: 10.1016/j.saa.2017.10.049.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.saa.2017.10.049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara‐Blanco A (2015) Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev 6‏</Citation>
        </Reference>
        <Reference>
          <Citation>Eiroa A, De-Armas G, Estela J, Cerda V. Critical approach to synchronous spectrofluorimetry. I Trends Anal Chem. 2010;29:885–901. doi: 10.1016/j.trac.2010.04.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trac.2010.04.010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macri A, Marini V, Sangalli G, Fucile C, Iester M, Mattioli F. An artificial aqueous humor as a standard matrix to assess drug concentration in the anterior chamber by high performance liquid chromatography methods. Clin Lab. 2015;61:47–52. doi: 10.7754/Clin.Lab.2014.140309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7754/Clin.Lab.2014.140309</ArticleId>
            <ArticleId IdType="pubmed">25807637</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohannesian L.  Handbook of pharmaceutical analysis. New York: Marcel Dekker; 2002. </Citation>
        </Reference>
        <Reference>
          <Citation>ICH Harmonised Tripartite Guidelines (2005) Validation of analytical procedures: text and methodology Q2(R1). http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. Accessed 29 August 2021</Citation>
        </Reference>
        <Reference>
          <Citation>Miller J, Miller JC.  Statistics and Chemometrics for Analytical Chemistry. London: Pearson Education Limited; 2018. </Citation>
        </Reference>
        <Reference>
          <Citation>Płotka-Wasylka J. A new tool for the evaluation of the analytical procedure: Green Analytical Procedure Index. Talanta. 2018;181:204–209. doi: 10.1016/j.talanta.2018.01.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.talanta.2018.01.013</ArticleId>
            <ArticleId IdType="pubmed">29426502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gałuszka A, Konieczka P, Migaszewski ZM, Namies'nik J. Analytical Eco-Scale for assessing the greenness of analytical procedures. Trends Anal Chem. 2012;37:61–72. doi: 10.1016/j.trac.2012.03.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trac.2012.03.013</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
